Use of ADNF polypeptides for treating peripheral neurotoxicity
AssigneeRamot at Tel-Aviv University Ltd.
InventorsIllana Gozes, James Miller
Life of this patent
Estimating the term…
Abstract
This invention relates to the use of ADNF polypeptides in the treatment of neurotoxicity induced by chemical agents or by disease processes. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences such as NAP and SAL, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain their respective active core sites.
Claims24
A method for treating peripheral neurotoxicity in a subject, the method comprising administering a therapeutically effective amount of an ADNF polypeptide to a subject in need thereof, wherein the ADNF polypeptide is a member selected from the group consisting of:
- (a) an ADNF I polypeptide comprising an active core site having the following amino acid sequence:
- Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:1);
- (b) an ADNF III polypeptide comprising an active core site having the following amino acid sequence:
- Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln (SEQ ID NO:2), and
- (c) a mixture of the ADNF I polypeptide of part (a) and the ADNF III polypeptide of part (b);
- wherein said peripheral neurotoxicity is a consequence of treatment with one or more chemical agents.
Dependencies are inferred from the claim text.